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Abstract
‘‘PEG-like Nanoprobes’’ (PN’s) are pharmacokinetically and optically tunable nanomaterials whose disposition in biological
systems can be determined by fluorescence or radioactivity. PN’s feature a unique design where a single PEG polymer
surrounds a short fluorochrome and radiometal bearing peptide, and endows the resulting nanoprobe with
pharmacokinetic control (based on molecular weight of the PEG selected) and optical tunability (based on the
fluorochrome selected), while the chelate provides a radiolabeling option. PN’s were used to image brain capillary
angiography (intravital 2-photon microscopy), tumor capillary permeability (intravital fluorescent microscopy), and the
tumor enhanced permeability and retention (EPR) effect (
111In-PN and SPECT). Clinical applications of PN’s include use as
long blood half-life fluorochromes for intraoperative angiography, for measurements of capillary permeability in breast
cancer lesions, and to image EPR by SPECT, for stratifying patient candidates for long-circulating nanomedicines that may
utilize the EPR mechanism.
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Introduction
A design for multimodal, fluorescent/radioactive imaging
agents embodying a versatile, simple, and clinically translateable
platform has yet to be fully recognized. An ideal design would
allow pharmacokinetic and optical tuning with a radiolabeling
option, and be readily eliminated after providing diagnostic
information, to lessen the chances of delayed side effects. Though
a variety of novel nanomaterials have been described (e.g.
nanoshells, carbon nanotubes, dendrimers, quantum dots), many
suffer from a lack of clinical experience and a lack of
understanding of their toxicity and elimination.
We introduce ‘‘PEG-like Nanoprobes’’ (PN’s) which employ a
single PEG polymer to surround a central fluorochrome and
chelate bearing peptide, a unique and clinically translateable
design that confers pharmacokinetic and optical tunability on
fluorescent and radioactive nanomaterials. PN’s exploit PEG-
fluorochrome shielding [1] which has been used in the design of
integrin binding RGD peptides, administered with peritumoral
injection and which diffuse through the interstitium into a tumor,
increasing tumor targeting and reducing normal organ uptake
compared to that obtained with IV administration [2]. The use of
a PEG in PN design is compared with the use of PEGylated in
other nanomaterials [3–6] in Figure 1A. (Support for this
configuration of PEG with PN’s is provided at end of the
Discussion).
The PN design allows the pharmacokinetics of fluorochromes
and radiometals to be optimized for specific applications by
varying the size of the PEG, a widely available polymer recognized
as safe after extensive clinical use [7–9]. Clinical applications of the
passively targeted (pharmacokinetically targeted) PN’s described
are discussed further below; these include intraoperative fluores-
cent angiography [10], fluorescent measurements of breast lesion
capillary permeability, and imaging the enhanced permeability
and retention (EPR) effect of tumors by SPECT. The EPR effect is
thought to be important in the efficacy of long-circulating
nanomedicines generally [11,12], and specifically with doxil, a
doxorubicin liposome [13], and with abraxane, a paclitaxel/
albumin complex [14]. Imaging tumor EPR effects might serve to
select patients most likely to benefit from nanomedicines.
Results
1. Synthesis and Characterization
To demonstrate the optical and pharmacokinetic tunability of
PEG-like Nanoprobes, we synthesized PN’s using different
fluorochromes, and different PEG polymers, as shown in
Figures 1B and 1C. After synthesis of the N-terminal DOTA-
bearing peptide, a thiol reactive fluorochrome is reacted with
cysteine thiol, followed reaction of a PEG-NHS ester with lysine
side chain. Details of the synthesis are provided in Schemes S1-
S7 in File S1. All peptides are C-terminal amides with the amide
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side chain nitrogens, the C-terminal amide is not chemically
reactive. The use of the IR-783 fluorochrome and 5 kDa PEG
(Figure 1B) yields a PN with an absorption maxima of 783 nm
and diameter of 4.3 nm; this is denoted as PN(783)4.3. The use of
a Cy3 fluorochrome and a 30 kDa PEG (Figure 1C) yields a PN
with an absorption maxima of 545 nm and a diameter of 10.0 nm;
this is denoted as PN(545)10.0. Table 1 summarizes PN’s made in
PN nomenclature (column 1) or peptide nomenclature (column 2).
PN’s were synthesized with IR-783, Cy3 and fluorescein, with
PEG’s ranging from 2 kDa to 40 kDa. Purification and charac-
terization of PN’s is shown in Figure S1 in File S1.
We determined the molecular weights of PN’s from mass
spectroscopy (Table 1, column 4). PN molecular weights
reported are the sum of its components: the PEG polymer, and the
peptide bearing a chelate and fluorochrome, i.e., the (DOTA)Lys-
Cys(Fl) peptide, where Fl indicates IR-783, Cy3 or fluorescein. For
example, as shown in Table 1, PN(783)4.3 has a molecular weight
of 6.29 kDa which results from the 1.3258 kDa (DOTA)Lys-
Cys(IR-783) peptide and the 5 kDa PEG.
To determine the volumes of PN’s in solution, we performed the
FPLC experiments shown in Figure 2. FPLC chromatograms are
shown for PN’s bearing the IR-783 fluorochrome with PEG’s
ranging from 2 to 40 kDa (Figure 2A). FPLC was calibrated with
globular protein standards, and globular protein equivalent
molecular volumes (in kDa) were obtained (Table 1, column 5).
Next, these globular protein equivalent molecular volumes were
converted to PN diameters in nm using the relationship:
R~0:066M
1=3 where M is the molecular weight of a globular
protein expressed in daltons [15]. PN diameters ranged from 3.0
to 11.7 nm, which means PN’s can be smaller or larger than
albumin (MW=67 kDa; diameter=5.4 nm, by the formula
above). Thus Table 1 column 5 gives the PN volumes obtained
from FPLC expressed in two ways: (i) as the molecular weight in
kDa of globular proteins with equivalent volumes, permitting size
comparison of PN’s to proteins, and, (ii) as spherical diameters
(‘‘Dia.’’) in nm, permitting size comparisons of a PN to relative to
other nanomaterials. We confirmed the sizes obtained with FPLC
by measuring the size of PN(783)11.7 by dynamic light scattering
(11.7 nm). See Figure S3 in File S1. Smaller PN’s did not scatter
sufficient light for accurate size determination by this technique.
An analysis of PN composition indicates their PEG component
largely determines both the nanoprobe’s composition and volume.
Consider PN(783)4.3 from Table 1, columns 4 and 5. This PN
consists of the (DOTA)Lys-Cys(IR783) (MW=1.3258 kDa) pep-
tide and a PEG (MW=5 kDa), giving it a composition that is 79%
PEG, (5000 Da/6290 Da). On a volume basis, the globular
equivalent protein volume of this PN was 35.2 kDa (corresponding
to a sphere with a diameter of 4.3 nm), which is a far larger
volume than would be expected based on nanoprobe mass
(6.29 kDa). Others have shown that PEG’s are extended, water
infiltrated structures whose dimensions in solution are bigger than
might be indicated from their mass [16]. Thus PN’s consist of a
relatively long PEG polymer which provides most of nanoprobe
mass and volume, and which surrounds a chelate and fluoro-
chrome-bearing peptide as shown in Figure 1A. (Evidence for
PEG on the outside and peptide on the inside is summarized in the
end of the Discussion section below.) In contrast many PEGylated
proteins and liposomes are obtained by attaching multiple PEG’s
to the surfaces of starting materials, Figure 1A.
Linking the fluorochrome and the PEG significantly increased
the quantum yields of fluorochrome-bearing peptides as summa-
rized in Table 1 (column 6). (The p values showing significances
are in Figure S2 in File S1). The attachment of a 2 kDa PEG to
(DOTA)Lys-Cys(IR-783) (i.e. yielding PN(783)3.0), resulted in
significantly less improvement in quantum yield than larger PEG
polymers; this was scored as ‘‘incomplete PEG-fluorochrome
shielding’’ and only PN’s made with PEG’s of 5 kDa or greater
were studied in biological systems. PEG attachment increased
quantum yields in all cases, but as discussed below the magnitude
of PEG generated improvement varied with the fluorochrome
chosen. A mechanism for the PEG improvement of quantum yield
is fluorochrome shielding, or the blocking of fluorochrome-
fluorochrome interactions that result in quenching [1].
We next examined the non-specific binding (NSB) of PN’s to
HT-29 cells based on the assumption that NSB minimization will
correlate with a desirable minimization of post-IV injection
retention. As noted above, after diagnostic drugs generate their
added information, retention can only increase the risks of delayed
toxicity. The attachment of PEG decreased the non-specific
Figure 1. Reaction with PEG polymers and fluorochrome and
DOTA bearing peptides yields PEG-like Nanoprobes (PN’s). A)
Syntheses of PEG-like Nanoprobe (PN’s). The peptide (DOTA)Lys-
Cys(Fluor.), with an N-terminal DOTA, a variable fluorochrome (Fluor.)
attached to the cysteine side chain, and a single primary amine, reacts
with the NHS ester of a variable PEG. In the conventional PEGylations of
proteins or nanoparticles, multiple PEG’s provide a PEG bearing surface.
This approach yields materials with a PEG to protein ratio or with a PEG
surface density. B) Synthesis of the PN denoted PN(783)4.3. A 5 kDa
PEG is reacted with the (DOTA)Lys-Cys(IR-783) peptide. The diameter
(by FPLC) is 4.3 nm and the absorption maximum is 783 nm, hence
PN(783)4.3. C) A 30 kDa PEG is reacted with the (DOTA)Lys-Cys(Cy3)
peptide. The diameter is 10.0 nm and an absorption maximum is
545 nm, hence, PN(545)10.0. A list of PN’s and their properties is given
in Table 1.
doi:10.1371/journal.pone.0095406.g001
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the cutoff for unstained cells seen with FACS (Table 1, column
7). The FACS analyses used to measure NSB’s are provided in
Figure S4 in File S1. As with quantum yield, reduction in cell
NSB is highly fluorochrome dependent, with the IR-783 peptide
showing a high NSB, and profound reduction by PEG attachment,
while the fluorescein peptide had a low NSB, even without PEG.
To examine whether the PN size was independent of the
fluorochrome selected, PN’s made with IR-783, Cy3 and
fluorescein were analyzed by FPLC (Figures 2A, 2B, 2C).
With the 5 kDa PEG, PN diameters were 4.3 nm (magenta
chromatograms of Figures 2A–2C) for PN’s with each fluoro-
chrome. With the 30 kDa PEG and these fluorochromes (blue
chromatograms, Figures 2A–2C), PN diameters were now
10.0 nm. Thus, the PEG we selected determined PN size,
regardless of fluorochrome used.
To see if the variable PN size could be translated into tunable
pharmacokinetics, it was essential to first establish that PN’s
circulated at PEG-determined, pre-injection dimensions. Mice
were injected with PN’s and FPLC chromatograms of serum
samples, taken at various times post injection (Figures 2D, 2E
and 2F), compared with pre-injection PN samples. By using PN’s
absorbing at 783 nm, chromatograms from the sera of injected
mice reflect this PN, since there are no compounds in serum that
absorb at this wavelength. With the FPLC chromatograms of
PN(783)10.0 (Figure 2D), peaks from a pre-injection sample or
from serum samples at 21 or 40 minutes had identical peak elution
volumes, indicating this PN circulates at its pre-injection size.
Similarly, peaks for PN(783)6.1 (Figure 2E) and PN(783)4.3
(Figure 2F) where identical for pre-injection samples and for
nanoprobes in the sera of injected mice. Thus, molecular weight of
the PEG chosen determines PN dimensions in vitro and those
dimensions are maintained after injection.
Since PN’s circulate at PEG-determined sizes, they are size-
variable nanomaterials that undergo transcapillary passage as their
injected form, see Figure 2G. In contrast, albumin-binding
compounds like indocyanine green (ICG), used clinically to
determine transcapillary passage (below), exist as albumin bound
and free forms. PN’s are size variable, multimodal nanomaterials
that can be used for determination of capillary permeability
without the uncertainties presented by albumin bound and free
forms.
The effect of PEG on PN elimination from surface fluorescence
measurements is shown in Figure 3. Surface fluorescence images
for representative animals are shown and total surface fluorescence
is quantified in bar graphs to the right of the image. A non-PEG
bearing (DOTA)Lys-Cys(IR-783) peptide showed slow and
incomplete elimination (Figure 3A), while PN(783)4.3,
(Figure 3B), a PN with a 5 kDa PEG attached, showed bladder
accumulation (arrow) at only 20 minutes post injection.
PN(783)10.0, which was larger than albumin with a diameter of
5.4 nm showed a vascular phase at 1 h, with excellent elimination
at 48 h. The pharmacokinetics and biodistributions of these PN’s
is further analyzed below.
2. Pharmacokinetic Modeling and Pharmacokinetic
Control
To assess the relationship between PN dimensions and
transcapillary passage, the classic two compartment pharmacoki-
netic model (Figure 4A) [17] was applied to PN(783)10.0
(Figure 4B) and PN(783)4.3 (Figures 4C). After injection into
normal mice, blood concentrations exhibited an initial fast
exponential decay (vascular escape), followed by a slow exponen-
tial decay (whole body clearance). The three microscopic rate
constants for the two-compartment model are given in Figures 4B
and 4C. Further details on the two-compartment model are
provided in the Supplement with a summary of all pharmacoki-
netic constants (Table S1). The rapid initial fall of PN blood
concentration is due to vascular escape, as occurs with fluorescent
dextrans [18,19].
Table 1. Summary of PEG-like Nanoprobes (PN’s).
PN
Designation
Peptide
Designation
Abs/em
(nm)
MW,
(kDa) Obs*
Volume FPLC
Dia. (Fig. 2a)**
Quant. Yield
(Fig. S3)***
Cell NSB
(Fig. S4)***
Not Appl. (DOTA)Lys-Cys Not Appl. 0.6356 Not Appl. Not Appl. Not Appl.
Not Appl. (DOTA)Lys-Cys(IR-783) 789/807 1.3258 Not Appl. 0.05360.008 9561%
PN(783)3.0 (DOTA)Lys(PEG 2 kDa)-Cys(IR-783) 789/810 3.34 11.2 kDa 3.0 nm 0.1360.02 5061%
PN(783)4.3 (DOTA)Lys(PEG 5 kDa)-Cys(IR-783) 789/810 6.29 35.2 kDa 4.3 nm 0.1660.03 2061%
PN(783)6.1 (DOTA)Lys(PEG 10 kDa)-Cys(IR-783) 789/810 11.41 100.7 kDa 6.1 nm 0.1660.03 1461%
PN(783)8.4 (DOTA)Lys(PEG 20 kDa)-Cys(IR 783) 789/810 21.28 262.5 kDa 8.4 nm 0.1660.04 1461%
PN(783)10.0 (DOTA)Lys(PEG 30 kDa)-Cys(IR-783) 789/810 30.62 435.4 kDa 10.0 nm 0.1660.04 1861%
PN(783)11.7 (DOTA)Lys(PEG
40 kDa)-Cys(IR-783)
789/809 45.00 690 kDa 11.7 nm 0.1660.02 1761%
Not Appl. (DOTA)Lys-Cys(Cy3) 544/559 1.2138 Not Appl. 0.3260.07 9861%
PN(545)4.3 (DOTA)Lys(PEG 5 kDa)-Cys(Cy3) 545/560 6.18 35 kDa 0.5960.09 3161%
PN(545)10.0 (DOTA)Lys(PEG 30 kDa)-Cys(Cy3) 545/560 30.51 435 kDa 0.6160.10 1561%
Not Appl. (DOTA)Lys-Cys(Fl) 497/521 1.0626 Not Appl. 0.5060.11 0.460.1%
PN(497)4.3 (DOTA)Lys(PEG 5 kDa)-Cys(Fl) 497/521 6.04 35 kDa 0.5960.06 0.260.1%
PN(497)10.0 (DOTA)Lys(PEG 30 kDa)-Cys(Fl) 497/521 30.36 435 kDa 0.6060.08 0.1% 60.1%
*M.W. Obs.=molecular weights were determined from mass spectrometry results.
**Volumes are expressed as diameters in nm (to enable comparison with nanomaterials) and as the equivalent volumes of proteins (to enable comparison with
proteins).
***Values are means61 S.D.
doi:10.1371/journal.pone.0095406.t001
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interstitial compartments using the values from Figure 4B are
shown in Figure 4D. Three pharmacokinetic phases shown are a
vascular phase (approximately for 1 h post injection), an interstitial
phase at (at 10–25 h), and an enhanced permeability retention
(EPR)-based uptake phase (by a tumor) at 48 h. These phases were
further examined with fluorescence imaging techniques, SPECT/
CT and radioactive organ biodistribution studies below.
3. Fluorescent Imaging and Optical Tunability of PN’s
A feature of PN design is that the fluorochrome can be selected
to optimize optical properties for different applications. To image
the vascular pharmacokinetic phase with two photon microscopy,
PN(497)10.0 was used because its fluorescein is readily excited in
the two photon mode. (Note that with whole animal surface
fluorescence imaging (Figure 3), PN’s bearing IR-783 were used
because of far greater tissue penetration of their near infrared
light.) Figure 5A shows intravital fluorescence microscopy of
mouse brain capillaries, with the normal blood brain barrier
blocking transcapillary passage to the interstitium. To further
examine the vascular and interstitial phases, a dorsal skinfold
chamber was used for the intravital, two photon microscopy of a
mCherry expressing HT-29 tumor (Figure 5B). At ten minutes
post-injection, PN(497)10.0 (green) was confined to the vasculature
at the periphery of the mCherry tumor cells (red). At 20 h post-
Figure 2. Tuning PN size, optical properties and PN circulating form. A) FPLC chromatograms of size-variable PN’s (constant IR-783
fluorochrome, variable PEG’s) are shown. Diameters are given in Table 1. B,C) Tuning PN size with different fluorochromes. The 5 kDa PEG yielded the
magenta coded chromatograms with diameters of 4.3 nm regardless of the fluorochrome used. They are PN(783)4.3 (2A), PN(545)4.3 (2B), and
PN(497)4.3 (2C). The 30 kDa PEG yielded the blue coded PN’s of 10 nm. Therefore PN dimensions are determined by PEG and independent of the
fluorochrome selected. (D,E,F) FPLC chromatograms of PN’s are shown before (pre) and from the sera of injected mice. PN’s were PN(783)10.0 (2D),
PN(783) 6.1 (2E), and PN(783)4.3 (2F). After injection, PN’s circulate at their PEG-determined and variable pre-injection sizes. (G) Since PN’s circulate
at PEG-determined, pre-injection sizes, they cross capillaries at those sizes. ICG binds albumin and can cross capillaries in two forms. "FL  " is the 
Pharmacokinetically and Optically Tunable PEG-Nanomaterials
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fluorescein fluorochrome.
doi:10.1371/journal.pone.0095406.g002injection, the PN was seen in the interstitium at the tumor
periphery.
The EPR effect with the HT-29 tumor and PN(545)10.0 was
demonstrated with surface fluorescence measurements of tumor as
shown in Figure 5C. With skin removed, an overlay of tumor
mCherry (green) and PN(545)10.0 (purple) gave a white superim-
position. To determine the cells responsible for the accumulation
of PN(783)10.0 seen with surface fluorescence (Figure 5C), we
employed confocal microscopy of mCherry/HT29 tumor sections
(Figure 5D). PN(497)10.0 was seen in mCherry/HT29 cells,
presumably by fluid phase pinocytosis of rapidly dividing cells,
since PEG does not bind known receptors.
4. Radiolabeled PN’s for SPECT/CT, Biodistribution and
Elimination
To demonstrate a multimodal imaging capability, the ability of
111In-PN(783)10.0 (or its non-radioactive counterpart,
PN(783)10.0) to image the EPR effect of the HT-29 tumor was
determined by SPECT/CT (Figure 6A) and whole animal
surface fluorescence (Figure 6B). Initially (2 h post-injection) by
SPECT or surface fluorescence, PN(783)10.0 exhibited a broad
vascular and interstitial distribution as predicted by the two
compartment model which was generated from the time
dependence of PN blood concentration (Figure 4B, 4D). At
48 h, PN(783)10.0 was seen only in the tumor with SPECT and
surface fluorescence, reflecting tomographic slice selection of
SPECT and the proximity of the tumor to surface. Consequently
radioactive biodistribution studies were performed to quantify
tumor and normal organ uptake.
Organ biodistribution studies with
111In-PN(783)10.0 at 24 h
and 48 h post-injection are shown in Figure 6C. At 48 h post
injection, 4.7160.38% of the injected dose (ID) was in the liver,
despite the fact that with a diameter of 10 nm this PN is
considerably larger than albumin (diameter=5.4 nm). In addition,
only 0.4460.02% of the injected dose was in the kidney, which
typically accumulates high levels of radiolabeled peptides due to
renal peptide transporters [20,21]. Organ concentrations are
provided in Figure S5 in File S1. Whole body radioactivity
decreased with a half-life of 7.8 h (Figure 6D) and was only
6.4160.57% of injected dose by 192 h. Thus PN’s show a
combination of large size, slow pharmacokinetics and low
retention.
5. PN Serum Stability
An important requirement of nanoprobes used to study slow
passive, pharmacokinetic processes is stability in biological fluids.
We therefore examined the stability of PN(783)4.3 and
PN(783)10.0 in mouse sera by three techniques: FPLC (size) total
probe fluorescence and
111In binding over a period of 48 h. As
shown by FPLC chromatograms in Figures 7A and 7B,
PN(783)4.3 and PN(783)10.0 retained their size, consistent post-
injection sizes being unchanged from pre-injection sizes
(Figure 2). Fluorescence of PN(783)4.3 and PN(783)10.0 was
also unchanged over this period (Figure 7C). Finally, we
111In-
labeled both PN’s and determined the fraction of radioactivity
associated with PN by HPLC as shown in Figure 7D. In mouse
sera, PN’s exhibit a stable size, a stable fluorescence, and a stable
binding of
111In.
Discussion
PEG is often attached to the surfaces of proteins or nanopar-
ticles to obtain improved properties (Figure 1A). In contrast PN’s
employ a single PEG polymer to surround a central fluorochrome
and radiometal bearing peptide, enabling the nanoprobe to be
detected by two modalities, and providing the nanoprobe with
diameters in nanometer size range.
The PN design allows optical tunability based on fluorochrome
selection. Thus, we used PN(783)4.3 and PN(783)10.0 (fluoro-
chrome = IR-783, absorption maxima=783 nm for both PN’s)
to demonstrate PEG’s enhancement of elimination by whole
animal surface fluorescence imaging (Figure 3). On the other
hand, with intravital microscopy of capillaries, run in either the
two-photon mode (Figure 5A) or in the conventional fluorescence
mode (Figure 5B), PN(497)10.0 was employed (fluorochrome =
fluorescein, absorption maxima=497 nm). With intravital mi-
croscopy, the higher quantum yields of fluorochromes with shorter
absorption and emission maxima may outweigh the greater tissue
penetrating properties of near infrared fluorochromes.
PEG attachment significantly increased quantum yield and
decreased non-specific binding to cells, relative to the values
obtained with unPEGylated fluorochrome-bearing peptides
(Table 1, columns 6 and 7). However, the magnitude of these
benefits varied with the fluorochrome selected. With the
(DOTA)Lys-Cys(IR-783) peptide, PEGylation increased the quan-
tum yield from 0.053 to 0.16 or three fold, while with (DOTA)Lys-
Cys(Fluorescein) peptide, PEGylation increased quantum yield
significantly (p,0.05) but more modestly, from 0.50 to 0.59 or
18%. Previous studies [1] indicated PEGylated, fluorochrome-
bearing peptides have absorption spectra in PBS similar to their
Figure 3. Role PEG in determining elimination by surface
fluorescence imaging. A) Animals were injected with unPEGylated
peptide and imaged at the times indicated. Bar graph gives whole
animal surface fluorescence determined as means and standard
deviations, n=6. B) With the 5 kDa PEG attached, PN(783)4.3 is
obtained, which shows renal elimination within 20 minutes (arrow). C)
With the 30 kDa PEG, PN(783)10.0 is obtained, which shows a long
vascular phase followed by elimination. Biodistribution and elimination
of
111In-PN(783)10.0 is shown in Figure 6.
doi:10.1371/journal.pone.0095406.g003
Pharmacokinetically and Optically Tunable PEG-Nanomaterials
PLOS ONE | www.plosone.org 5 April 2014 | Volume 9 | Issue 4 | e95406unstacked absorption spectra in methanol. Hence, a mechanism
for the quantum yield improvement afforded by PEGylation is the
blockage of fluorochrome/fluorochrome stacking, and fluoro-
chrome self-quenching, that occur in aqueous solutions. It appears
that longer wavelength fluorochromes have stronger fluoro-
chrome/fluorochrome stacking interactions, which result in more
quenching, which is blocked by PEG and which gives rise to larger
increases in quantum yield.
The PN design also offers a pharmacokinetic tunability based
on PEG selection, as shown in Figure 4, where the pharmaco-
kinetics of PN(783)4.3 and PN(783)10.0 were compared using the
classic two-compartment model. The initial, rapid drop in serum
fluorescence with both PN’s reflects the high capillary permeability
of materials in this size range seen with mice. For example,
fluorescent dextrans with molecular weights between 10 and
70 kDa have high capillary permeabilities, reaching peaks of
interstitial fluorescence in less than 1 hour post injection [18]. In
humans, a specific PN is expected to have substantially slower
pharmacokinetics than in mice. Thus PN(783)4.3, which had a
Kperm of 1.74 h
21 in mice (Figure 4C), which can be expressed as
a half-life of 23.7 minutes, might be satisfactory as a ‘‘long’’
circulating fluorochrome for intraoperative angiography in
humans. ICG, with a blood half-life of 2.5–3 minutes (manufac-
turer’s package insert) in humans, is currently used for intraop-
erative fluorescent angiography in neurosurgery [22] or recon-
structive surgery [23,24].
PN’s are nanomaterials that exhibit pharmacokinetics and
biodistributions that differ from other fluorochromes and other
peptides. As noted, many fluorochromes behave like ICG, binding
albumin and undergoing rapid clearance by the hepatobiliary
transport system of hepatocytes [25–27]. In contrast after
injection, PN(783)10.0 underwent a relatively slow vascular
permeability (Kperm~0:67h{1) and slow elimination
(Kelim~0:24h{1), see Figure 4B In addition,
111In-PN(783)10.0
had a hepatic retention of 4.7160.38% ID (48 h, Figure 6C),
though its diameter was significantly larger than albumin (5.4 nm).
Whole body radioactivity measurements at 48 h indicated only
13.7560.74% of ID was retained in the animal (Figure 6D), and
most of this was in the blood (8.7461.44% of ID, Figure 6C).
The presence of
111In-PN(783)10.0 in blood results from a
combination of nanoprobe transport from the interstitium to the
blood, Kvas,return and the slow rate of elimination, Kelim, as shown
with the two compartment model in Figure 4A. Many
radiolabeled peptides are substrates for renal peptide transporters,
which make the kidney the organ of highest tracer concentration
(and organ of dose limiting toxicity) [20,21,28]. In contrast,
111In-
PN(783)10.0 exhibited a renal retention of only 0.4460.02% of ID
(48 h post-injection).
111In-PN(783)10.0 is poorly recognized by
the cellular transport systems operating in vivo, such as the
hepatobiliary transport system of hepatocytes which recognizes
albumin bound fluorochromes, and renal peptide transporters,
which recognize many radiolabeled peptides.
We propose that PN’s consist of a PEG polymer surrounding a
fluorochrome and chelate bearing peptide (Figure 1A) because of
the variety of observations indicating a profound lack of
recognition of PN’s in biological systems. These are: (i) PEG
reduces nonspecific interactions between fluorochrome bearing
peptides with cells (Table 1, column 7), (ii) PN’s circulate at
their PEG determined pre-injection sizes, without binding albumin
(Figures 2D–2F), a feature that permits pharmacokinetic
tunability (Figure 4), (iii) after injection, PEG enhances elimina-
tion (Figure 3) and, (iv) the biodistribution and elimination of
111In-PN(783)10.0 (Figure 6) shows a lack of recognition by
hepatobiliary transport system and renal peptide transporters.
In preliminary clinical trials ICG and fluorescent imaging has
been used for the determination of the capillary permeability of
Figure 4. Variable PN pharmacokinetics analyzed by the two compartment pharmacokinetic model in normal mice. A) Two
compartment pharmacokinetic model showing three microscopic rate constants. Serum fluorescence for PN(783)10.0 B) and PN(783)4.3 C) after
injection are shown. Data were fit to the two compartment model with data provided in Table 1. D) Time courses for blood and interstitial
fluorescence of PN(783)10.0 using microkinetic constants from B).
doi:10.1371/journal.pone.0095406.g004
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cancerous status [29]. However, a complex ICG infusion protocol
[30] was needed to overcome ICG’s short blood half-life, see
above. In addition, as shown in Figure 2G, ICG can undergo
transcapillary passage as the high molecular weight albumin-
bound form or as the low molecular weight unbound form. Using
PN’s to visualize the capillary permeability, as we did for the HT-
29 tumor (Figure 5B), is not subject to ambiguities about the
molecular form undergoing transcapillary passage. With their
pharmacokinetic and optical tunability, PN’s may be superior to
ICG for determination of lesion permeability.
To demonstrate an important application for a radiolabeled PN,
we imaged tumor EPR effects by SPECT/CT as shown in
Figure 6A. Long-circulating liposomes and polymer conjugates,
approved or in clinical trials, may utilize the EPR effect, in part,
for their efficacy [11,31,32]. Imaging the EPR effect might lead to
improved patient selection for the administration of these often-
expensive medications.
In conclusion, PN’s rely on a single long PEG polymer to
surround fluorochrome and metal chelate reporters, blocking
interactions with cells and biomolecules in vivo and in vitro. In the
vascular phase PN’s might be suitable as controlled blood half-life,
intraoperative fluorescent angiographic agents, while in their
transition to the interstitial phase used to determine capillary
permeability by either fluorescence of SPECT. Finally, the
retention of radiolabeled PN’s by tumors might be used to image
the EPR effect by SPECT. Thus, the single PEG polymer design
of PN’s offers excellent prospects for clinical translation, with uses
in multiple clinical applications and multiple imaging modalities.
Materials and Methods
All animal experiments in this work were approved by the
Institutional Review Committee of the Massachusetts General
Hospital. Animals were sacrificed by carbon dioxide inhalation.
Protected L-amino acids, PyBOP and Rink Amide MBHA resin
were from Novabiochem (EMD Biosciences). Other special
chemicals were from other sources: DOTA(CO2Bu
t)3 (Macrocy-
clics), mPEG-NHS esters (Creative PEGworks or NOF corpora-
tion, Japan) IR-783 (Sigma-Aldrich), fluorescein-5-maleimide
(Thermo Scientific), and Cy3-maleimide was (Lumiprobe).
The synthesis of PN’s involves three steps: (i) synthesis of the
(DOTA)Lys-Cys peptide (Scheme S1 in File S1), (ii) reaction of
thiol reactive fluorochrome to the cysteine thiol (Schemes
S2,S3,S4 in File S1) and, (iii) reaction of an NHS-ester of PEG
with variable molecular weight to the lysine side chain (Figure S1
and Schemes S5, S6, S7 in File S1). Details of each synthesis
and radiolabeling (Scheme S8 in File S1) are given in the
supplement.
PN Characterization
The mass spec of low molecular weight (MW) materials were
obtained by MS-ESI Micromass (Waters) and high MW molecules
were determined through MALDI-TOF analyses at the Tufts
Figure 5. Fluorescent imaging of three pharmacokinetic phases of PN’s with diameters of 10 nm. A) Vascular phase, two photon
microscopy of brain vasculature of normal mice. Mice underwent a craniotomy and implantation of a transparent window. Vessel intensity drops due
vascular escape, but there is no interstitial fluorescence in the brain due to the blood brain barrier. Scale marker=50 microns. B) Intravital confocal
microscopy of the vascular and interstitial phases of an mCherry expressing HT-29 xenograft. During the vascular phase (10 min post-injection),
vessels are imaged, without interstitial fluorescence. During the interstitial phase (20 h post-injection), interstitial fluorescence is prominent. Scale
marker=20 microns. C) Surface fluorescence/X-ray imaging of the tumor retention phase of PN(545)10.0. Shown are the HT-29/mCherry tumor with
the skin removed as a white light image, mCherry tumor fluorescence (green), PN(545)10.0 fluorescence (purple) and the green/purple over lay
(white). D) Confocal microscopy of the tumor retention phase of PN(497)10.0. Shown are a sectioned HT-29 mCherry expressing tumor with nuclei
stained blue (DAPI), mCherry tumor cells (red), PN(497)10.0 (green) and a green/red overlay (yellow).
doi:10.1371/journal.pone.0095406.g005
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delivery modules) employed an eluant A (0.1% TFA/water) and
eluant B (0.1% TFA and 9.9% water in acetonitrile). Probe size
(volume) was determined by FPLC using an A ¨KTA Purifier 10
and SuperdexTM 200 10/300GL column (GE Healthcare) with a
running buffer of 0.05 M sodium phosphate, 0.1 M NaCl (0.1%
Tween, pH 7.2) and flow rate of 0.8 ml/min. Standards (GE
Healthcare) were Ferritin, Ribonuclease A, Carbonic Anhydrase,
and Conalbumin and Blue Dextran 2000. To obtain probe
volumes, Mr (apparent molecular weight based on size exclusion
retention) was plotted versus Kav. Kav~ve{vo
vt{vo,V t=total volume,
Ve=elution volume, Vo=void volume.
Purity
Peptides were characterized by mass spectroscopy. FPLC was
used remove low molecular weight peptide (Figure S1A in File
S1) and confirm final product purity (Figure 2). The mass spec of
PN(783)4.3 is shown in Figure S1B in File S1.
Figure 6. Multimodal imaging of EPR tumor targeting and elimination of PN(783)10.0. A) SPECT/CT images of two mice bearing two HT-
29 tumors as a function of time after injection. At 2 h post injection, agent is in the blood and interstitium. By 24 h post-injection tumors are
becoming apparent as agent is being cleared. At 48 h, labeling is highly tumor selective. B) Surface fluorescence imaging of two additional mice
bearing the same tumor. By surface fluorescence, as with SPECT, labeling is highly tumor selective at 48 h. C) Organ biodistribution was obtained by
dissection and
111In counting at 24 h and 48 h post-injection. Data are means and standard deviations, n=5. D) A whole animal radioactivity
elimination curve. Data are means and standard deviations, with extremely small standard deviations, n=5.
doi:10.1371/journal.pone.0095406.g006
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20 nmoles of PN(783)4.3, PN(783)6.1, or PN(783)10.0 was
injected (IV, tail vein) into nude mice (female; 25–30 g; 6–8 weeks
old; nu/nu). At the indicated time, 50 ml of blood was collected
with microhematocrit capillary tube (Fisher Scientific) from the
tail, and transferred to Eppendorf microcentrifuge tube with
anticoagulant (EDTA) coating (Fisher Scientific). Tubes were
centrifuged (5000 rpm for 5 min), and the supernatant was
injected to the FPLC, a A ¨KTA Purifier 10 with SuperdexTM
200 10/300GL column.
Pharmacokinetics
Groups of 5 nude mice (female; 25–30 g; 6–8 weeks old; nu/nu)
were injected (tail vein, IV) with 10 nmole of PN(783)4.3 or
PN(783)10.0. 50 ml of blood was collected from tail tip at the
indicated times. The blood was processed as above, and diluted
(25 ml plasma, 700 ml of PBS). Fluorescence was measured with
Cary Eclipse Fluorescence Spectrophotometer, excitation at
765 nm and emission from 790 to 880 nm. The fluorescence
intensity at 806 nm was plotted over time, and the data was fit to a
biexponential, two phase decay curve. The fast and slow
distribution half-life was given by the two phase decay fit with
Graphpad Prism software.
Two Compartment Model
From the two phase decay fit, a biexponential equation for blood
concentration as a function of time, cp~A.e{atzB.e{bt,w a s
obtained. By the relation of macro constants and micro constants:
kvas,return~
A.bzB.a
AzB
, kelim~
a.b
kvas,return
, kperm~azb{kvas,return{
kelim, micro constants k’s can be obtained, and the half-life was
calculated by t1=2
~0:693=k, as described in [17]. The curve for
interstitium concentration vs. time was fit with MATLAB based on the
curve of blood concentration vs. time.
Whole Animal Surface Fluorescence
A Kodak FX multispectral imaging system was used (Care-
stream Molecular Imaging, Rochester, NY). Excitation at multiple
wavelengths (620, 650, 690, 710, 720, 730, 750 and 760 nm) with
the emission at 830 nm was setup for IR-783 spectrum; Excitation
at multiple wavelengths (420, 440, 460, 480, 510, 520, 530, and
540 nm) with the emission at 600 nm was setup for Cy3 spectrum;
Excitation at multiple wavelengths (450, 470, 510, 520, 530, 540,
550, 570, and 590 nm) with the emission at 700 nm was setup for
mCherry; with manufacturer’s software to separate (unmix) the
IR-783 spectrum, Cy3 spectrum, or mCherry spectrum from skin
autofluorescence and chlorophyll fluorescence from food. X-ray
images were taken after fluorescence images. Animals were
anesthetized with 2% isoflurane with O2 flow (2 l/min) during
imaging.
Tumor Surface Fluorescence (Skin Removed)
The PN(783)10.0 or PN(545)10.0 (10 nmoles, 100 mL) was
injected (IV, tail vein), the skin around tumor was removed at 48 h
post injection, with tumor visualized as mCherry fluorescence
using the Kodak FX.
Tumor Model
Female nude mice (25–30 g; 6–8 weeks old; nu/nu) were
anesthetized with 2% isoflurane/O2. HT-29 or mCherry-HT-29
cells were detached, pelleted and 200 ml of cell suspension
containing 10
6 cells in Matrigel (BD Bioscience) was injected
subcutaneously into right and left shoulders. Tumors were allowed
to grow 5–7 days before experiments. All experiments were
Figure 7. Stability of PN’s in mouse serum. The stability of PN(783)4.3 A) or PN(783)10.0 B) was examined by incubating nanoprobes for the
indicated times and subjecting samples to FPLC. Arrows are the retention times of PN’s from Figure 2A, color coded as in that figure. Fluorochrome
size is unchanged for both PN’s. C) Stability of PN fluorescence. PN(783)4.3 or PN(783)10.0 were incubated as indicated and fluorescence determined.
D) Stability of
111In binding to PN’s.
111In-PN(783)4.3 or
111In-PN(783)10.0 were incubated as indicated and radioactivity associated with the PN
determined by HPLC. Exemplary chromatograms are provided; see Figure S6 in File S1.
doi:10.1371/journal.pone.0095406.g007
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cells were a gift from Dr. Darshini Kuruppu.
SPECT/CT
The imaging was performed by Triumph II multimodality
imaging system (Gamma Medica Ideas, LLC) comprising
XSPECT with four CZT (Cadmium Zink Telluride) detectors
and X-O CT with CMOS detector. SPECT data of the
111In-
labeled compound was acquired for 60 min using 5-pinhole
collimators and processed with 3D-OSEM algorithm using 4
subsets and 5 iterations. 3-dimensional CT data was processed
with modified Feldkamp software. The processed 3D-images were
fused and displayed with VIVID software package installed to the
Triumph data management. Animals were under isoflurane
anesthesia (1.5%) with O2 flow (1.5 l/min) and kept warm during
the imaging with a heated animal bed.
Organ Biodistribution
150 mlo f
111In-labeled PN(783)10.0 (400 mCi, ,2 nmole) were
injected to tumor-bearing animals by tail vein (IV). 24 h or 48 h
later, animals were sacrificed, and tumors, blood, liver, spleen,
stomach, kidneys, small intestine, lung, heart, tail, fat, and muscle,
were collected. Radioactivity was measured with Perkin Elmer,
Wizard2 2480 gamma counter.
Confocal Imaging
The mCherry-HT-29 tumor sample was collected at 48 h post
IV injection with PN(497)10.0, and then cryosectioned with
thickness of 5 mm. The tumor section was fixed with 4% PFA,
mounted with 90% glycerol/10% PBS (at pH 8.5 for best
fluorescein fluorescence), and stained with DAPI. Confocal
imaging was performed on a Zeiss LSM510 laser scanning
confocal microscope (Zeiss Axiophot, Carl Zeiss, Jena, Germany).
A 405 nm diode Laser, 488 nm argon laser, and 561 nm diode
laser were used for the excitation of DAPI, fluorescein, and
mCherry, respectively. A primary dichroic HFT 405/488/561
was used in combination with an LP420 emission filter for DAPI,
BP505-530 for fluorescein, and LP575 for mCherry. Images were
analyzed with ImageJ64.
Brain Vascular Phase Imaging
Craniotomies in C57Bl/6J wildtype mice (from Jackson
Laboratory, Bar Harbor, ME. USA, 3–4 months old) were
performed as described [33]. Animals were anesthetized using 2%
isoflurane in balanced oxygen, and then a 5 mm diameter skull
flap was removed. A craniotomy was performed, and the exposed
brain area was covered by an 8 mm round glass coverslip, which
was sealed to the skull with dental cement. This procedure allowed
a transparent window into the mouse brain for use with in vivo
microscopy of the cerebrovasculature. Mice were allowed 2–3
weeks for complete recovery after the craniotomy prior to imaging.
Mice were anesthetized with 2% isoflurane in balanced oxygen
and secured in a custom stereotaxic frame, which fit into the
microscope stage. The cerebrovasculature was imaged using the
Olympus FluoView FV1000MPE multiphoton laser-scanning
system mounted on an Olympus BX61WI microscope (Olympus,
Tokyo, Japan). A DeepSee Mai Tai Ti:sapphire mode-locked laser
(Mai Tai; Spectra-Physics, Fremont, CA) produced two photon
fluorescence with 800 nm excitation. The vessels were imaged at
depth of 45 to 100 mm from the surface of the brain. Two nmoles
of PN(497)10.0 was injected with images analyzed Fluoview and
ImageJ.
Imaging the Tumor Interstitium
Dorsal skinfold chamber (DSFC) tumors were grown in female
nude mice (nu/nu; 25–30 g; 6–8 weeks old) with modifications
from previously published techniques [34,35]. 10
6 mCherry-HT-
29 tumor cells in matrixgel (BD) were subcutaneously injected in
the back of mice ,1.5 cm left of the dorsal midline approximately
halfway from the neck to the tail base. 4 days later, DSFCs were
installed in a way that the tumors were centered in the imaging
window of the chamber and accessible to longitudinal investigation
by MP-IVM. On days 2, 3, and 4 days after tumor DSFC
implantation, when tumors were typically 3 mm in diameter,
image stacks of tumor tissue were recorded under general
anesthesia with Ketamine and Xylazine. Ten nmoles of
PN(497)10.0 was injected (IV, tail vein).
Multiphoton excitation was obtained through DeepSee and MaiTai
Ti:sapphire lasers (Newport/Spectra-Physics) tuned to 920 and
1000 nm to excite all fluorescent probes used. Stacks of 11 square
optical sections with 4 mm z-spacing were acquired every 20 sec on an
Ultima IV multiphoton microscope (Prairie Technologies) using a
20X/0.95 NA lens with optical zoom of up to 1x to provide image
volumes 30 mm in depth and 200 mm in width. Emitted fluorescence
was detected through 460/50, 525/50, 595/50, 660/40 band-pass
filters and non-descanned detectors to generate four-color images.
Sequences of image stacks were transformed into volume-rendered,
time-lapse movies with Imaris software (Bitplane).
PN Stability
1) Fluorescence: 0.5 nmole of PN(783)4.3 or PN(783)10.0 was
incubated in 100 ml of mouse serum (abcam, ab7486) at 37uC for
2 h, 24 h or 48 h. Fluorescence intensity was measured in 1.5 ml
cuvette at each time point by diluting with 700 ml of PBS. 2) Size:
10 nmole of PN(783)4.3 or 5 nmole of PN(783)10.0 was incubated
in 200 ml of mouse serum at 37uC. 40 ml of mixture was injected
into FPLC instrument to measure the size of the nanoprobe at 2 h,
24 h or 48 h. 3) Radiochemical:
111In-labeled PN(783)4.3 or
111In-labeled PN(783)10.0 was incubated at 37uC in mouse serum
for 2 h, 24 h, or 48 h. Radiolabeling stability was determined by
HPLC with C18 column.
Supporting Information
File S1 Supplementary files. Schemes S1 to S8, reactions and
conditions used in the synthesis of PN’s. Figure S1, Purification of
PN’s by FPLC and PN characterization by mass spectroscopy.
Figure S2, Effect of PEG on quantum yields. Figure S3, Dynamic
light scattering measurement for PN(783)10.0 and PN(783)11.7.
Figure S4, Effect of PEGylation on non-specific binding to cells by
single channel FACS. Figure S5, Biodistribution, as organ
concentrations, of PN(783)10.0. Corresponding organ biodistribu-
tions are provided in Figure 6. Figure S6, HPLC chromatograms
of
111In-labeled PN’s mouse serum.
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